8 results on '"Riccò, Beatrice"'
Search Results
2. Pembrolizumab in Vaginal Carcinoma: A Case Report and Review of the Literature.
- Author
-
Vitale, Maria Giuseppa, Nasso, Cecilia, Riccò, Beatrice, Bocconi, Alessandro, Chiavelli, Chiara, Baldessari, Cinzia, Pipitone, Stefania, Bacchelli, Francesca, Botticelli, Laura, Dominici, Massimo, and Sabbatini, Roberto
- Subjects
LITERATURE reviews ,VAGINAL cancer ,PEMBROLIZUMAB ,CARCINOMA ,GOVERNMENT aid ,VULVAR cancer ,GYNECOLOGIC cancer - Abstract
Introduction: Vaginal cancer is a rare gynecologic malignancy. While in a localized disease, concurrent chemoradiation grants local control and better overall survival, in a metastatic setting, the management options are very limited. Furthermore, recurrent cervical, vulvar, and vaginal carcinomas notoriously develop resistance to treatment, and consequently, their prognosis is still poor. Case Presentation: We herein present the case of a woman with a nodal relapse of vaginal carcinoma, effectively treated with third-line immunotherapy. We will also provide a review of the literature on the new therapeutic strategies for advanced vaginal carcinoma, with a focus on pembrolizumab immunotherapy. Conclusion: Pembrolizumab might represent a promising option for the management of vaginal and vulvar cancer, but data to support its use in this setting are still lacking. This case highlights the need for further investigation and trial designs for this rare disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Optimizing the Continuum of Care in Gastric Cancer.
- Author
-
Riccò, Beatrice, Martinelli, Giulio, Bardasi, Camilla, Dominici, Massimo, Spallanzani, Andrea, and Salati, Massimiliano
- Subjects
- *
CONTINUUM of care , *STOMACH cancer , *CANCER treatment , *IMMUNE checkpoint inhibitors , *SURVIVAL rate - Abstract
Gastric cancer (GC) still ranks as the fifth most common malignancy and the fourth leading cause of cancer-related death worldwide. Despite the recent progress in the therapeutic algorithm of the advanced disease with the advent of immune checkpoint inhibitors (ICIs) and next-generation HER2-directed therapies, survival rates remain poor, with a median survival hardly exceeding 12 months. Furthermore, only 40% of patients remain eligible for second- and later-line treatments due to the aggressiveness of the disease and the rapid deterioration of performance status (PS). Thus, current research is focusing either on the identification of novel treatment options or the development of personalized strategies to optimize the continuum of care and ultimately improve patients' outcome. In this article, we provide an overview of the current treatment landscape for advanced GC with a particular emphasis on later-line treatments and outline novel perspectives on the horizon. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Management of PALB2‐associated breast cancer: A literature review and case report.
- Author
-
Toss, Angela, Ponzoni, Ornella, Riccò, Beatrice, Piombino, Claudia, Moscetti, Luca, Combi, Francesca, Palma, Enza, Papi, Simona, Tenedini, Elena, Tazzioli, Giovanni, Dominici, Massimo, and Cortesi, Laura
- Subjects
LITERATURE reviews ,BREAST cancer ,TUMOR suppressor genes ,IMMUNE checkpoint inhibitors ,OVARIAN cancer ,HORMONE receptors ,PANCREATIC tumors - Abstract
Key Clinical Message: Germline pathogenic variants (PV) of the PALB2 tumor suppressor gene are associated with an increased risk of breast, pancreatic, and ovarian cancer. In previous research, PALB2‐associated breast cancer showed aggressive clinicopathological phenotypes, particularly triple‐negative subtype, and higher mortality regardless of tumor stage, type of chemotherapy nor hormone receptor status. The identification of this germline alteration may have an impact on clinical management of breast cancer (BC) from the surgical approach to the systemic treatment choice. We herein report the case of a patient with a germline PV of PALB2, diagnosed with locally advanced PD‐L1 positive triple‐negative BC, who progressed after an immune checkpoint inhibitor (ICI)‐containing regimen and then experienced a pathologic complete response after platinum‐based chemotherapy. This case report hints a major role of the germline PALB2 alteration compared to the PD‐L1 expression as cancer driver and gives us the opportunity to extensively review and discuss the available literature on the optimal management of PALB2‐associated BC. Overall, our case report and review of the literature provide additional evidence that the germline analysis of PALB2 gene should be included in routine genetic testing for predictive purposes and to refine treatment algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition.
- Author
-
Medici, Bianca, Riccò, Beatrice, Caffari, Eugenia, Zaniboni, Silvia, Salati, Massimiliano, Spallanzani, Andrea, Garajovà, Ingrid, Benatti, Stefania, Chiavelli, Chiara, Dominici, Massimo, and Gelsomino, Fabio
- Subjects
- *
EARLY detection of cancer , *METASTASIS , *POPULATION geography , *DISEASE incidence , *COLORECTAL cancer , *DISEASE risk factors - Abstract
Simple Summary: In this review, the authors will discuss the highlights of early onset colon cancer (EOCRC), an increasing but still unclear phenomenon. Indeed, the risk factors are largely similar to classic colon cancer (CRC), but it is still unclear what causes an increased risk of CRC at an early age. In addition, the issue of screening, which allows early diagnosis of the disease, is also important; the younger segment of the population is not included in such programs except if they belong to the highest-risk groups. If the phenomenon of EOCRC becomes more prominent, screening programs will have to be reviewed but with consideration of the consequences for health economics. In this review, we will focus on the epidemiological, prognostic, clinico-pathological, molecular, and therapeutic features of EOCRC; in particular, we will try to highlight the characteristics of the metastatic stage and the differences with CRC in older segments of the population. Despite a recent overall decrease in colorectal cancer (CRC) incidence and mortality, there has been a significant rise in CRC diagnoses in young adults. Early onset colorectal cancer (EOCRC) is defined as CRC diagnosed before the age of 50. Possible predisposing conditions include not only genetic syndromes but also other risk factors, such as microbiome alteration, antibiotic exposure, obesity, diabetes mellitus, and inflammatory bowel disease. EOCRC tends to be diagnosed later than in the older counterpart because of a lack of awareness and the fact that screening for CRC usually starts at the age of 50. Furthermore, CRC in young adults seems to be related to unique molecular features and more aggressive clinical behavior. This paper aims to provide an in-depth review of this poorly understood subject, with a comprehensive review of the state of the art and considerations for future perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Personalized Systemic Therapies in Hereditary Cancer Syndromes.
- Author
-
Mastrodomenico, Luciana, Piombino, Claudia, Riccò, Beatrice, Barbieri, Elena, Venturelli, Marta, Piacentini, Federico, Dominici, Massimo, Cortesi, Laura, and Toss, Angela
- Subjects
HEREDITARY cancer syndromes ,MEDULLARY thyroid carcinoma ,CANCER treatment ,IMMUNE checkpoint inhibitors ,NANOMEDICINE ,HEREDITARY nonpolyposis colorectal cancer ,PROGRAMMED cell death 1 receptors - Abstract
Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants (PVs) that lead to an increased risk of developing certain types of cancer, frequently at an earlier age than in the rest of the population. The germline PVs promote cancer development, growth and survival, and may represent an ideal target for the personalized treatment of hereditary tumors. PARP inhibitors for the treatment of BRCA and PALB2-associated tumors, immune checkpoint inhibitors for tumors associated with the Lynch Syndrome, HIF-2α inhibitor in the VHL-related cancers and, finally, selective RET inhibitors for the treatment of MEN2-associated medullary thyroid cancer are the most successful examples of how a germline PVs can be exploited to develop effective personalized therapies and improve the outcome of these patients. The present review aims to describe and discuss the personalized systemic therapies for inherited cancer syndromes that have been developed and investigated in clinical trials in recent decades. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. THU-251 - CD73high biliary tract cancer (BTC): a molecularly-defined subtype with distinct clinical implications
- Author
-
Salati, Massimiliano, Barbato, Anna, Piscopo, Fabiola, Evangelista, Lorenzo, Gambardella, Gennaro, Sarnataro, Sergio, Petrillo, Angelica, Daniele, Bruno, Pisapia, Pasquale, Salatiello, Maria, Malapelle, Umberto, Troncone, Giancarlo, Spallanzani, Andrea, Gelsomino, Fabio, Ricco’, Beatrice, Iuliano, Antonella, Reggiani-Bonetti, Luca, Rourke, Colm O, Andersen, Jesper, Dominici, Massimo, Franco, Brunella, and Carotenuto, Pietro
- Published
- 2023
- Full Text
- View/download PDF
8. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
- Author
-
Riccò B, Salati M, Reggiani Bonetti L, Dominici M, and Luppi G
- Subjects
- Aged, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Biomarkers, Tumor, Carcinoma, Neuroendocrine diagnosis, Carcinoma, Neuroendocrine mortality, Humans, Immunohistochemistry, Male, Molecular Targeted Therapy, Neoplasm Staging, Stomach Neoplasms diagnosis, Stomach Neoplasms mortality, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Neuroendocrine drug therapy, Carcinoma, Neuroendocrine genetics, DNA Mismatch Repair, Programmed Cell Death 1 Receptor antagonists & inhibitors, Stomach Neoplasms drug therapy, Stomach Neoplasms genetics
- Abstract
Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is an uncommon and aggressive tumor arising throughout the entire gastrointestinal tract. Treatment options are limited, and survival is dismal with conventional therapies., Case Description: We present the case of a 66-year-old man who was diagnosed with a locally advanced MANEC of the gastroesophageal junction. He was treated with perioperative chemotherapy and total gastrectomy. After anastomotic tumor recurrence was detected, he underwent three systemic regimens, including chemoradiotherapy. The patient was then tested for mismatch repair (MMR) protein status, revealing defective expression of MLH1 and PMS2 proteins. Treatment with anti-programmed death 1 (PD-1) receptor monoclonal antibody pembrolizumab was started and radiologic response is ongoing after 11 months. Clinical benefit was evident, and no immune therapy-related side effect was detected., Conclusions: To our knowledge, this is the first report of a heavily pretreated and rapidly progressing deficient MMR gastroesophageal MANEC experiencing a durable benefit from anti-PD1 treatment.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.